This seminar will explore the key considerations around biotech valuations when preparing for out-licencing deals for specific assets, considering a public listing or when raising the next round of financing.
- Why every biotech should create a valuation model
- Common mistakes in valuations and how to avoid them
- Gaining the upper hand in negotiations
Speaker: Thobias Thornblad, CEO of MSC Nordics